| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Based on the reduction of net value of three distinct paired combinations (α3β4, α4β2), α3β2), and α7 homomeric neurons (nAChR), the IC50 (area) were 390, 1.2, 110, 75, 440, 460, 430, 2.7, 1.0, respectively. nAChR-IN-1 (100 nM) suppresses nAChR by 90%. accountable for the ACh responses at 1.4 and 18.3 nM [1].
|
|---|---|
| ln Vivo |
In a time-dependent way, nAChR-IN-1 (20 mg/kg; subcutaneous injection; single dosage) improves mice's hypokinesia and hypothermia caused by nicotine [1].
|
| Animal Protocol |
Animal/Disease Models: Nicotine-induced mouse model [1]
Doses: 20 mg/kg Route of Administration: subcutaneous injection; single dose; 15 minutes before injection of nicotine (1.5 mg/kg) Experimental Results: Mouse activity increased even with nicotine Caused reduction in motor activity. Has no effect on body temperature. Animal/Disease Models: Mouse tail flick and hot plate model [1] Doses: 0, 0.1, 1, 5 mg/kg Route of Administration: subcutaneous injection; single dose Experimental Results: block the analgesic effect of nicotine in the hot plate. Time-dependent blockade of nicotine-induced analgesia. |
| References | |
| Additional Infomation |
Heptanoic acid (2,2,6,6-tetramethyl-4-piperidinyl) ester is a fatty acid ester.
|
| Molecular Formula |
C16H31NO2
|
|---|---|
| Molecular Weight |
269.429
|
| Exact Mass |
305.212
|
| Elemental Analysis |
C, 71.33; H, 11.60; N, 5.20; O, 11.88
|
| CAS # |
849461-90-1
|
| Related CAS # |
nAChR-IN-1 hydrochloride;849461-91-2
|
| PubChem CID |
11207937
|
| Appearance |
Colorless to light yellow liquid
|
| Boiling Point |
356.5ºC at 760 mmHg
|
| Flash Point |
169.4ºC
|
| LogP |
4.94
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
19
|
| Complexity |
281
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.CCCCCCC(OC1CC(C)(C)NC(C)(C)C1)=O
|
| InChi Key |
PWWKJRFUJIFGGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H31NO2/c1-6-7-8-9-10-14(18)19-13-11-15(2,3)17-16(4,5)12-13/h13,17H,6-12H2,1-5H3
|
| Chemical Name |
(2,2,6,6-tetramethylpiperidin-4-yl) heptanoate
|
| Synonyms |
nAChR-IN-1 ;TMPH; TMPH inhibitor;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~371.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7115 mL | 18.5577 mL | 37.1154 mL | |
| 5 mM | 0.7423 mL | 3.7115 mL | 7.4231 mL | |
| 10 mM | 0.3712 mL | 1.8558 mL | 3.7115 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
